High Roller Technologies, an online gaming and prediction markets company, is a Diamond sponsor of the NEXTPredict 2026 conference held October 22-23 in New York City. Their Chief Business Officer, Flip Pidot, will host a panel debating which party will control the Senate after the midterm elections, using prediction market data. This event highlights High Roller's role in advancing prediction markets and engaging with industry leaders. The conference gathers key players from gaming, finance, and regulatory sectors to discuss market trends and innovations.
High Roller Technologies is a Diamond sponsor of the NEXTPredict 2026 conference. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Oct 19, 2026 18:21 WIB: out of 134 priced US stocks, 73 rose and 34 fell today. Notable movers include Allbirds Inc (BIRD) at USD 2.42 with a 1-day change of +1.89% and Quantumscape Corp (QS) at USD 4.09 with +1.74%, while Packaging Corporation of America (PKG) declined by -1.71% to USD 231.97.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
